BMC infectious diseases · 2026
Risk factors for tigecycline-associated drug-induced liver injury in critically Ill patients: a 2020-2023 retrospective study from a Chinese hospital.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yonghui, Zhang Siying, Shen Miaozhe, Zhang Ke
Аннотация
BACKGROUND: Tigecycline is extensively used in Chinese intensive care unit (ICU) for multidrug-resistant infections, yet the profile of its associated drug-induced liver injury (DILI) requires further investigation. Therefore, this study was designed to explore the incidence, identify independent predictors, and characterize the dose-response relationship and timing of tigecycline-associated DILI in critically ill patients.
METHODS: This single-center, retrospective cohort study enrolled all critically ill patients (n = 309) who received intravenous tigecycline between 2020 and 2023. DILI was diagnosed according to established international biochemical criteria (n = 71). We employed Pearson correlation analysis and multivariable logistic regression to assess relationships between clinical factors and DILI development. The dose-response relationship between tigecycline exposure and DILI risk was characterized using ROC analysis and generalized additive models (GAM). Time-to-onset of DILI was evaluated using Kaplan-Meier analysis to estimate cumulative incidence and median event time.
RESULTS: The incidence of tigecycline-associated DILI was 23.0%. Multivariable analysis identified total duration of tigecycline therapy (OR = 2.01 per week, 95% CI: 1.42-2.92) and cumulative tigecycline dose (OR = 1.51 per gram, 95% CI: 1.19-1.94) as significant independent risk factors. The dose-response relationship was found to be non-linear, with a GAM revealing an initial increase in risk that attenuated at higher cumulative doses (P < 0.05). The cumulative dose of tigecycline was associated with DILI (AUC = 0.647). The median time to DILI onset among affected patients was 4 days; the Kaplan‑Meier estimate of median DILI‑free survival in the full cohort was 18 days.
CONCLUSIONS: In patients who develop DILI, the median onset time of 4 days underscores the importance of early hepatic monitoring; the 18‑day Kaplan‑Meier estimate further supports extended vigilance throughout prolonged therapy. Cumulative dose and treatment duration should be managed to mitigate the risk of hepatotoxicity.
CLINICAL TRIAL NUMBER: Not applicable.
METHODS: This single-center, retrospective cohort study enrolled all critically ill patients (n = 309) who received intravenous tigecycline between 2020 and 2023. DILI was diagnosed according to established international biochemical criteria (n = 71). We employed Pearson correlation analysis and multivariable logistic regression to assess relationships between clinical factors and DILI development. The dose-response relationship between tigecycline exposure and DILI risk was characterized using ROC analysis and generalized additive models (GAM). Time-to-onset of DILI was evaluated using Kaplan-Meier analysis to estimate cumulative incidence and median event time.
RESULTS: The incidence of tigecycline-associated DILI was 23.0%. Multivariable analysis identified total duration of tigecycline therapy (OR = 2.01 per week, 95% CI: 1.42-2.92) and cumulative tigecycline dose (OR = 1.51 per gram, 95% CI: 1.19-1.94) as significant independent risk factors. The dose-response relationship was found to be non-linear, with a GAM revealing an initial increase in risk that attenuated at higher cumulative doses (P < 0.05). The cumulative dose of tigecycline was associated with DILI (AUC = 0.647). The median time to DILI onset among affected patients was 4 days; the Kaplan‑Meier estimate of median DILI‑free survival in the full cohort was 18 days.
CONCLUSIONS: In patients who develop DILI, the median onset time of 4 days underscores the importance of early hepatic monitoring; the 18‑day Kaplan‑Meier estimate further supports extended vigilance throughout prolonged therapy. Cumulative dose and treatment duration should be managed to mitigate the risk of hepatotoxicity.
CLINICAL TRIAL NUMBER: Not applicable.